Skip to main content

Beckwith-Wiedemann Syndrome — Patient Cohort — Clinical Pathway: ICU and Inpatient

Beckwith-Wiedemann Syndrome Clinical Pathway — N/IICU

Patient Cohort

This pathway guides the care of neonates/infants born at the CHOP SDU or referred from outside institutions for further evaluation and treatment with overgrowth features such as giant omphalocele and/or constellation of findings suspicious for BWS.

Beckwith-Wiedemann Syndrome (BWS) is a human genomic imprinting disorder with much phenotypic variability. Variable phenotypes might include:

  • Macrosomia
  • Lateralized overgrowth
  • Macroglossia
  • Abdominal wall defects
  • Neonatal hypoglycemia
  • Predisposition to embryonal tumours1

BWS is caused mainly by epigenetic or genetic changes in the chromosome 11p15.5 region.1

BWS Clinical Features (use .bwschart to score)

Cardinal Features
2 pts for each feature
Suggestive Features
1 pt for each feature
  • Macroglossia
  • Omphalocele
  • Lateralized overgrowth/hemihypertrophy
  • Wilms tumor or nephroblastomatosis
  • Hyperinsulinism
  • Adrenal cortex cytomegaly
  • Placental mesenchymal dysplasia
  • Pancreatic adenomatosis
  • Macrosomia (birth wt > 2 SD above mean)
  • Facial nevus simplex
  • Polyhydramnios/placentomegaly
  • Ear creases/pits
  • Transient Hypoglycemia, lasting < 1 wk
  • Typical BWS tumors:
    • Neuroblastoma
    • Rhabdomyosarcoma
    • Unilateral Wilms tumor
    • Hepatoblastoma
    • Adrenocortical carcinoma
    • Pheochromocytoma
  • Nephromegaly/hepatomegaly
  • Umbilical hernia and/or diastasis recti

Reference: Clinical and Molecular Diagnosis, Screening and Management of Beckwith–Wiedemann Syndrome: an International Consensus Statement  

 

Jump back to top